Aducanumab Gets a Green Flag from FDA for Alzheimer’s
The FDA recently, amidst some serious controversy approved an anti-amyloid-beta human monoclonal antibody, Aducanumab (Aduhelm) for the treatment of Alzheimer’s disease. The new treatment approved after 2003 is the first to target beta-amyloid to slow down the progression of AD. The results of three distinct randomized, dose-ranging studies (a total of 3382 patients) demonstrated time […]